Adverse Drug Events Associated With Remdesivir in Real-World Hospitalized Patients With COVID-19, Including Vulnerable Populations: A Retrospective Multicenter Study

BACKGROUND: Remdesivir is a US Food and Drug Administration-approved drug for coronavirus disease 2019 (COVID-19). Clinical trials were conducted under strictly controlled situations for a selected population, and their reported adverse events may not fully represent conditions in real-world patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Kang, Hyein, Kang, Chang Kyung, Im, Jae Hyoung, Cho, Yoonsook, Kang, Dong Yoon, Lee, Ju-Yeun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643246/
https://www.ncbi.nlm.nih.gov/pubmed/37967875
http://dx.doi.org/10.3346/jkms.2023.38.e346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643246/
https://www.ncbi.nlm.nih.gov/pubmed/37967875
http://dx.doi.org/10.3346/jkms.2023.38.e346

Ejemplares similares